What are the recommended treatments for acute pseudogout in a patient who cannot use colchicine?

Treatment for Pseudogout When Colchicine is Contraindicated

For acute pseudogout in patients who cannot take colchicine, use NSAIDs as first-line therapy, intra-articular corticosteroid injection for monoarticular disease, or systemic corticosteroids for polyarticular involvement. 1

First-Line Treatment Options

The EULAR guidelines explicitly address this clinical scenario, recognizing that colchicine and NSAIDs often have significant contraindications in the typical pseudogout patient population (older adults with comorbidities) 1. Here's the algorithmic approach:

For Monoarticular or Oligoarticular Disease:

• Joint aspiration followed by intra-articular corticosteroid injection is the preferred approach 1
• This provides rapid symptom relief while avoiding systemic drug exposure
• Standard precautions for corticosteroid injection apply (rule out infection first)

For Polyarticular Disease or When Injection is Not Feasible:

• Systemic corticosteroids are the treatment of choice 1
• This becomes particularly important when NSAIDs are also contraindicated due to renal impairment, cardiovascular disease, or gastrointestinal bleeding risk

NSAIDs as Alternative:

• Can be used if not contraindicated 1, 2
• However, the guidelines emphasize that NSAIDs carry substantial risks in older patients: gastrointestinal bleeding, cardiovascular events, and renal impairment 1
• Careful benefit-risk assessment is mandatory given the typical pseudogout patient has chronic renal impairment and multiple comorbidities 1

Supportive Measures (Always Include):

• Ice or cool packs to the affected joint 1, 2
• Temporary rest with weight restriction 1, 2
• These non-pharmacologic interventions are strongly supported and should be used alongside any pharmacologic therapy

Critical Clinical Pitfalls:

The evidence base is limited: There are no RCTs specifically for pseudogout treatment 1. Most recommendations are extrapolated from gout studies or based on clinical expertise. This makes the choice of corticosteroids particularly prudent when colchicine is contraindicated, as they have the broadest safety profile in the elderly population with comorbidities.

Why colchicine might be contraindicated: The FDA label details multiple scenarios including severe renal impairment (CrCl <30 mL/min), dialysis patients, severe hepatic impairment, or concurrent use of strong CYP3A4/P-gp inhibitors 3. Recognize that diarrhea is the first sign of colchicine toxicity 3.

Avoid the misdiagnosis trap: Up to 40% of patients diagnosed with gout actually have pseudogout 4. While both conditions can be treated with similar anti-inflammatory approaches, this highlights the importance of synovial fluid analysis when feasible.

Treatment Algorithm Summary:

1. Monoarticular/oligoarticular → Aspirate joint + intra-articular corticosteroid
2. Polyarticular or injection not feasible → Systemic corticosteroids
3. If steroids contraindicated → NSAIDs (with careful risk assessment)
4. Always add → Ice packs + temporary joint rest

There is no role for IL-1 inhibitors in pseudogout (unlike gout where they are second-line options 5), and there are currently no long-term preventive therapies for calcium pyrophosphate crystal formation 2.